The Patent Finder

Method and Pharmaceutical Composition for Use in the Treatment of Cancer

Universite Paris Diderot

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 9,198,949Method and Pharmaceutical Composition for Use in the Treatment of Cancer
In force
 · High confidence
UsedRemaining
Inserm (Institut National de la Sante et de la Recherche Medicale), Universite Pierre et Marie Curie Upmc, Universite Paris Diderot-Paris 7, Universite Paris Descartes and Assistance Publique-Hopitaux de ParisIn forceHigh confidence
Application 14/874,657Method and Pharmaceutical Composition for use in the Treatment of Cancer
Abandoned
Abandoned Nov 19, 2017
Assistance Publique-Hopitaux de ParisAbandonedAbandoned Nov 19, 2017
Application 15/687,692Method and Pharmaceutical Composition for Use in the Treatment of Cancer
Abandoned
Abandoned Oct 18, 2018
Inserm (Institut National de la Sante et de la Recherche Medicale), Universite Pierre et Marie Curie Upmc, Universite Paris Diderot- Paris 7, Universite Paris Descartes and Assistance Publique - Hopitaux de ParisAbandonedAbandoned Oct 18, 2018
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Universite Paris Diderot.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited